Liver CancerPub Date : 2022-12-05eCollection Date: 2023-08-01DOI: 10.1159/000528374
Haoting Shi, Jingxuan Huang, Shi Zhao, Yiwen Jin, Rong Cai, Jinjun Ran
{"title":"Trends and Disparities in Stage-Specific Incidence of Hepatocellular Carcinoma among US Adults, 2004-2019.","authors":"Haoting Shi, Jingxuan Huang, Shi Zhao, Yiwen Jin, Rong Cai, Jinjun Ran","doi":"10.1159/000528374","DOIUrl":"https://doi.org/10.1159/000528374","url":null,"abstract":"<p><strong>Introduction: </strong>The aim of this study was to determine the stage-specific incidence trend of hepatocellular carcinoma (HCC) among US adults.</p><p><strong>Methods: </strong>The age-adjusted incidence rate was extracted from Surveillance, Epidemiology, and End Results database for localized, regional, and distant HCC. Trend analyses were conducted in the overall population and stratified by demographic and sociodemographic variables. The annual percentage change (APC) in 2014-2019 was estimated to determine the stage-specific incidence trend.</p><p><strong>Results: </strong>Although the incidence of localized HCC significantly declined, the incidence for regional and distant HCC plateaued in 2014-2019 (APCs, 4.4% [95% CI, -0.2% to 9.3%] and -0.7% [95% CI, -1.8% to 0.5%], respectively) with age and race/ethnicity disparities. More pronounced increases for regional and distant HCC were observed among the elderly (APCs, 8.4% [95% CI, 4.8-12.2%] and 2.2% [95% CI, 1.7-2.7%] for regional and distant HCC, respectively), non-Hispanic white individuals (APCs, 4.0% [95% CI, 2.9-5.1%] and 1.5% [95% CI, 0.7-2.4%] for regional and distant HCC, respectively).</p><p><strong>Conclusions: </strong>Disparities in incidence trends may reflect the inequalities in access to primary health care. More efforts are still in great demand for the vulnerable population.</p>","PeriodicalId":18156,"journal":{"name":"Liver Cancer","volume":"12 3","pages":"277-280"},"PeriodicalIF":13.8,"publicationDate":"2022-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/8b/e1/lic-0012-0277.PMC10521315.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41106308","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Liver CancerPub Date : 2022-12-02DOI: 10.1159/000527592
{"title":"Acknowledgement to Reviewers","authors":"","doi":"10.1159/000527592","DOIUrl":"https://doi.org/10.1159/000527592","url":null,"abstract":"<br />Liver Cancer 2022;11:583–584","PeriodicalId":18156,"journal":{"name":"Liver Cancer","volume":"64 2","pages":""},"PeriodicalIF":13.8,"publicationDate":"2022-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138512626","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Liver CancerPub Date : 2022-12-01DOI: 10.1159/000525671
Daneng Li, Han Chong Toh, Philippe Merle, Kaoru Tsuchiya, Sairy Hernandez, Wendy Verret, Alan Nicholas, Masatoshi Kudo
{"title":"Atezolizumab plus Bevacizumab versus Sorafenib for Unresectable Hepatocellular Carcinoma: Results from Older Adults Enrolled in the IMbrave150 Randomized Clinical Trial.","authors":"Daneng Li, Han Chong Toh, Philippe Merle, Kaoru Tsuchiya, Sairy Hernandez, Wendy Verret, Alan Nicholas, Masatoshi Kudo","doi":"10.1159/000525671","DOIUrl":"https://doi.org/10.1159/000525671","url":null,"abstract":"<p><strong>Introduction: </strong>The efficacy of systemic first-line treatments in older adults with unresectable hepatocellular carcinoma (HCC) has not been well-studied. We compared the safety and efficacy of atezolizumab plus bevacizumab versus sorafenib as a first-line treatment in younger versus older patients with unresectable HCC.</p><p><strong>Methods: </strong>This global, phase 3, open-label, randomized clinical trial (IMbrave150) recruited patients aged ≥18 years with locally advanced metastatic or unresectable HCC, an Eastern Cooperative Oncology Group performance status score of 0 or 1, and Child-Pugh class A liver function who had not previously received systemic therapy for liver cancer. Patients received either 1,200 mg atezolizumab plus 15 mg/kg bevacizumab intravenously every 3 weeks or 400 mg sorafenib orally twice daily until loss of clinical benefit or unacceptable toxicity. Primary endpoints were overall survival (OS) and progression-free survival (PFS). Secondary outcomes were the incidence of adverse events and time to deterioration of patient-reported outcomes (PROs). This subgroup analysis evaluated safety and efficacy endpoints in patients <65 years, ≥65 to <75 years, and ≥75 years.</p><p><strong>Results: </strong>Of 501 patients, 165 patients were randomized to sorafenib and 336 were randomized to atezolizumab plus bevacizumab (175 patients <65 years; 106 patients ≥65 to <75 years; 55 patients ≥75 years). Across all age groups, patients receiving atezolizumab plus bevacizumab had longer median OS (<65: 18.0 vs. 12.2 months [HR, 0.57; 95% CI: 0.40-0.82]; ≥65 to <75: 19.4 vs. 14.9 months [HR, 0.80; 95% CI: 0.52-1.23]; ≥75: 24.0 vs. 18.0 months [HR, 0.72, 95% CI: 0.37-1.41]) and PFS than those receiving sorafenib. Time to deterioration for multiple PROs was delayed for patients receiving atezolizumab plus bevacizumab, including older adults. There were no clinically meaningful differences in toxicity between age groups.</p><p><strong>Conclusion: </strong>Atezolizumab plus bevacizumab is safe and effective in adults <65, ≥65 to <75, and ≥75. Treatment was well-tolerated even in elderly patients.</p>","PeriodicalId":18156,"journal":{"name":"Liver Cancer","volume":"11 6","pages":"558-571"},"PeriodicalIF":13.8,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/fd/c5/lic-0011-0558.PMC9801180.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10816922","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Liver CancerPub Date : 2022-12-01DOI: 10.1159/000525028
Kong-Ying Lin, Shi-Chuan Tang, Cheng-Wu Zhang, Yong-Yi Zeng, Tian Yang
{"title":"Impact of Antibiotics Use on Cancer-Related and All-Cause Mortality among Patients Receiving Immunotherapy for Advanced Hepatocellular Carcinoma.","authors":"Kong-Ying Lin, Shi-Chuan Tang, Cheng-Wu Zhang, Yong-Yi Zeng, Tian Yang","doi":"10.1159/000525028","DOIUrl":"https://doi.org/10.1159/000525028","url":null,"abstract":"<jats:p>None</jats:p>","PeriodicalId":18156,"journal":{"name":"Liver Cancer","volume":"11 6","pages":"576-577"},"PeriodicalIF":13.8,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/4e/b1/lic-0011-0576.PMC9801172.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10458342","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Chinese Expert Consensus on Immunotherapy for Hepatocellular Carcinoma (2021 Edition).","authors":"Yu Yang, Juxian Sun, Mengchao Wu, Wan Yee Lau, Shusen Zheng, Xue-Hao Wang, Xiaoping Chen, Jia Fan, Jiahong Dong, Jianqiang Cai, Minshan Chen, Yongjun Chen, Zhangjun Cheng, Chaoliu Dai, Jianzhen Shan, Cheng-You Du, Chihua Fang, Heping Hu, Zhili Ji, Weidong Jia, Gong Li, Jing Li, Jiangtao Li, Chang Liu, Fubao Liu, Yong Ma, Yilei Mao, Zuoxing Niu, Jie Shen, Jie Shi, Xuetao Shi, Wenjie Song, Hui-Chuan Sun, Guang Tan, Ran Tao, Xiaohu Wang, Tianfu Wen, Liqun Wu, Jinglin Xia, Bang-De Xiang, Maolin Yan, Mingang Ying, Ling Zhang, Xuewen Zhang, Zhao Chong Zeng, Yubao Zhang, Zhiwei Zhang, Jie Zhou, Cuncai Zhou, Jun Zhou, Ledu Zhou, Xinmin Zhou, Ji Zhu, Zhenyu Zhu, Qi Zhang, Qiu Li, Shuqun Cheng","doi":"10.1159/000526038","DOIUrl":"https://doi.org/10.1159/000526038","url":null,"abstract":"<p><strong>Background: </strong>Hepatocellular carcinoma (HCC) is one of the most common malignancies in China. Most HCC patients are first diagnosed at an advanced stage, and systemic treatments are the mainstay of treatment.</p><p><strong>Summary: </strong>In recent years, immune checkpoint inhibitors have made a breakthrough in the systemic treatment of middle-advanced HCC, breaking the single therapeutic pattern of molecular-targeted agents. To better guide the clinical treatment for effective and safe use of immunotherapeutic drugs, the Chinese Association of Liver Cancer and Chinese Medical Doctor Association has gathered multidisciplinary experts and scholars in relevant fields to formulate the \"Chinese Clinical Expert Consensus on Immunotherapy for Hepatocellular Carcinoma (2021)\" based on current clinical studies and clinical medication experience for reference in China.</p><p><strong>Key messages: </strong>The consensus contained 17 recommendations, including the preferred regimen for first- and second-line immunotherapy, evaluation and monitoring before/during/after treatment, management of complications, precautions for special patients, and potential population for immunotherapy.</p>","PeriodicalId":18156,"journal":{"name":"Liver Cancer","volume":"11 6","pages":"511-526"},"PeriodicalIF":13.8,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/09/02/lic-0011-0511.PMC9801175.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10458344","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
